title: PET Response-Guided Treatment of Hodgkin's Lymphoma: A Review of the Evidence and Active Clinical Trials.
abstract: Risk-adaptive therapy for Hodgkin's lymphoma focuses on treatment modifications based on assessment of response. [(18)F]Fluoro-deoxyglucose positron emission tomography (PET) performed during or after completion of chemotherapy is a strong prognostic factor for eventual treatment outcome. Conceptually, this strategy seeks to increase efficacy and minimize toxicity through the appropriate selection of patients for either therapy escalation (high-risk, PET positive) or de-escalation (low-risk, PET negative). Preliminary evidence with tailoring both chemotherapy (drug selection, number of cycles, and dose) and radiotherapy (omission or inclusion) is varied; however, numerous clinical trials seeking to validate this approach are ongoing. This paper summarizes the available evidence and active protocols involving PET response-adapted therapy for adult (early and advanced stages) Hodgkin's lymphoma.
authors.affiliation: Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Aridgides
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Bogart
authors.forename: Anna
authors.initials: A
authors.lastname: Shapiro
authors.forename: Ajeet
authors.initials: A
authors.lastname: Gajra